Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451516 | 0.92 | GSK3B (0.54) | GSK3BPARP10PTPN1EPHX2MAP4K4 | |
| SCHEMBL3454228 | 0.92 | GSK3B (0.54) | GSK3BPARP10PTPN1EPHX2MAP4K4 | |
| SCHEMBL3451514 | 0.92 | GSK3B (0.54) | GSK3BPARP10PTPN1EPHX2MAP4K4 | |
| SCHEMBL25180868 | 0.81 | PARP10 (0.51) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL3969375 | 0.80 | OPRK1 (0.50) | GSK3BPTPN1EPHX2 | |
| SCHEMBL1977190 | 0.77 | ALDH1A1 (0.70) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL204218 | 0.77 | GSK3B (0.70) | GSK3BPARP10PTPN1ALDH1A1 | |
| SCHEMBL25545459 | 0.76 | PDE4D (0.49) | PARP10EPHX2ALDH1A1LMNA | |
| SCHEMBL5722254 | 0.76 | MEN1 (0.50) | GSK3BPTPN1LMNA | |
| SCHEMBL4285489 | 0.76 | PARP10 (0.58) | PARP10EPHX2MAP4K4SENP8SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3237385-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | IDH1, IDH3B, IDH3A | GSK3B 715/4885PARP10 1309/4885PTPN1 933/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | GSK3B 715/4885PARP10 1309/4885PTPN1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.